[Weaning of young smokers using a transdermal nicotine patch].
To assess efficacy and tolerance of a transdermal nicotine system (TNS) as adjuvant to tobacco withdrawal, 112 young, nicotine-dependent cigarette smokers were treated for nine weeks with TNS (n = 56) or placebo (n = 56). Initial doses of nicotine (21 or 14 mg/24 h) were based on previous smoking habits and stepwise reduced to 7 mg/24 h if abstinence was achieved during medication. After treatment, 39.3% of the TNS users were abstinent versus 19.6% on placebo (p less than 0.05). The craving for cigarettes diminished steadily, but not more significantly on TNS medication. Tenseness, difficulty in concentration and feelings of hunger were consistently and in part significantly lessened in the TNS group. The other withdrawal symptoms were not influenced by TNS treatment. Nine-month follow-up cotinine-verified abstinence rates were 12.5% in the TNS and 3.6% in the placebo group (n. s.). Transient mild or moderate erythema at the application site appeared in 20% of the TNS and 6.3% of the placebo group, and 7.1% of the TNS users dropped out because of severe localized erythema. Other mild, transient, systemic side effects reported by 33.9% of the TNS and 26.8% of the placebo users (n. s.) did not lead to drop-outs.
Ehrsam
R E
RE
Institut für Sport der Med. Fakultät, Universität Basel.
Bühler
A
A
Müller
P
P
Mauli
D
D
Schumacher
P M
PM
Howald
H
H
Imhof
P R
PR
D000279:Administration, Cutaneous; D000328:Adult; D002248:Carbon Monoxide / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009538:Nicotine / Q000008:administration & dosage*; D012907:Smoking / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome
D009538:Nicotine; D002248:Carbon Monoxide